JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer
This is a prospective, single-arm phase II clinical study to evaluate the efficacy and safety of JS-201 combined with lenvatinib in the treatment of small-cell lung cancer that has failed previous chemotherapy combined with PD-L1. The primary observational endpoint is ORR, and the secondary observational endpoint is PFS, OS. The intervention mode is JS201 300mg i.v Q2w, lenvatinib 8mg po. Qd.
Small-cell Lung Cancer
DRUG: JS201 combine with Lenvatinib
ORR, Defined as the proportion of subjects in complete remission (CR) and partial remission (PR) to the total subjects, 1 year
PFS, Defined as the time from the beginning of treatment to the first imaging disease progression or death (whichever occurs first), 1 year
This is a prospective, single-arm phase II clinical study to evaluate the efficacy and safety of JS-201 combined with lenvatinib in the treatment of small-cell lung cancer that has failed previous chemotherapy combined with PD-L1. The primary observational endpoint is ORR, and the secondary observational endpoint is PFS, OS. The intervention mode is JS201 300mg i.v Q2w, lenvatinib 8mg po. Qd.